DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/zpfs4r/egfr1_signaling) has announced the addition of the "EGFR1 Signaling Pathway in Oncology Drug Pipeline Update 2015" report to their offering.
The EGFR1 signaling pathway activates the Ras/Raf/MAPK signaling modules.
There are today 400 companies plus partners developing 589 EGFR1 pathway targeting drugs in 2481 developmental projects in cancer. In addition, there are 5 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 360 drugs.
Egfr1 Signaling Pathway In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 273 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 267 out of the 269 studied drug targets so far have been recorded with somatic mutations.
The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 54 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Pipeline Breakdown According to Number of Drugs
- Marketed - 49
- Registered - 1
- Pre-registration - 6
- Phase III - 69
- Phase II - 229
- Phase I - 274
- Preclinical - 318
- No Data - 18
- Suspended - 5
Ceased - 360
Delivery Format: Desktop App plus Online Access to Updates (One Year)
For more information visit http://www.researchandmarkets.com/research/zpfs4r/egfr1_signaling